CTCFL

Across TCGA pan-cancer cohorts, CTCFL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CTCFL data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTCFL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CTCFL expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where CTCFL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.378	0.731	.002	29	view →
LSCC	DFS	Quartile	III,IV	0.383	0.868	.010	14	view →
UCEC	OS	Tertile	II,III,IV	0.568	1.000	.022	8	view →
GBM	DFS	Tertile	All	0.293	0.469	.014	8	view →
HNSC	DFS	Median	II,III,IV	0.896	0.974	.024	5	view →
CCRCC	DFS	Median	III,IV	0.804	0.550	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CTCFL–PDAC (OS)

Open the PDAC breakdown →